Low compliance is suspected as a major reason for treatment failure in hypertensive patients. To identify patients with low compliance at the commencement of antihypertensive treatment, the compliance praxis survey (COMPASS) was utilised. A total of 161 physicians identified 2389 hypertensive patients treated by ACEinhibitor. The physicians rated the compliance of the patients at baseline and at 6-month follow-up prospectively. Standard care was given. The mean age of patients was 64.5 years (54.4% women). The baseline overall score of compliance was medium to high in 97.3% of patients. A quarter of all patients (24.7%) were described as having difficulties to follow lifestyle changes, 22.3% lacked sufficient social support, and 31.0% were unwilling to obtain additional information about illness and treatment. Patients who had received prior treatment for cardiovascular disease were less compliant than those who received first treatment within this study (P ¼ 0.05). Younger (Po0.01), male patients (Po0.01), and those without prior cardiovascular disease (Po0.001) were significantly more likely to stop the antihypertensive treatment without a doctor's recommendation. Doctors' rating of compliance at baseline correlated well with ongoing treatment at 6-month follow-up. In conclusion, the COMPASS survey questionnaire is a useful instrument for doctors to differentiate between patients who lack resources and to then counsel patients based on their individual needs.
Introduction
Hypertension is a primary risk factor for heart disease and stroke. Together these illnesses accounted for more than 30 000 deaths in Austria in 1999, and cause 40% of all deaths each year in Austria. 1 Although many new drugs to control hypertension have been developed and have proven to be effective in the last 20 years, 2 and more patients are treated, 3 the success of treatment outside clinical trials is still unsatisfactory. 4 Low compliance of the subjectively mostly asymptomatic patients 5 is suspected as a major reason for this disappointing finding. [6] [7] [8] At least 30% of all prescriptions are never used by patients. 9 Others have estimated that approximately 30-50% of all patients are completely noncompliant, while only 25-33% adhere to the prescribed medication. 10 The term compliance today is frequently replaced by the term adherence to emphasise the importance of active patient decision and participation in medical treatment. However for the purpose of this study, we will use the term compliance while acknowledging the importance of the patients' self-regulatory role and a relationship of equals between patient and physician. Several strategies to increase compliance were discussed in the literature and were summarised by health organisations such as the WHO. 11, 12 To return from hypertension to normotension, changes in patients' usual behaviour are required (N ¼ normative behaviour). Behaviours reported to be involved in reducing high blood pressure are taking the subscribed medication regularly, following the doctor's advice, checking the blood pressure, reducing or stopping smoking, increasing the level of exercise, and reducing the intake of dietary fat. 10, [13] [14] [15] Other researchers have focused on the influence of the doctor-patient relationship on compliance (E ¼ effective structural circumstances) such as arranging definite follow-up appointments, the patient's involvement in planning, implementing and stabilising the treatment regimen, and considering the patients satisfaction with the outcome of a consultation. 16-l9 Compliance may also depend upon broader organisational aspects such as the complexity of the medication regimen, [20] [21] [22] the formulation and initiation of a risk reduction plan in hospitals, and the consistency of treatment regimens when patients are transferred from hospitals to family physicians. [23] [24] [25] The social network of patients can also influence their compliance (S ¼ social support). Social support was proven to be one of the most important factors when predicting compliance with nutritional changes. 26, 27 The most common interventions aimed to increase compliance focus on a patient's knowledge about the disease and/or treatment (W ¼ wisdom/ knowledge). [29] [30] [31] [32] [33] [34] [35] In most studies, patients with an enhanced understanding of the disease and its management have higher adherence rates, [29] [30] [31] whereas others could not find a clear knowledge-adherence relationship. 32 However, only 20% of hospital patients feel that they received enough and adequate information and education, and another 20% are completely unsatisfied with the information they received. 33 Individualised recommendations by physicians considering all four areas, Normative behaviour, Effective structural circumstances, Social support and Wisdom/knowledge (NESW), might lead to more favourable outcomes, since they can be tailored to fit the patient's current state of readiness to change. [36] [37] [38] [39] emphasises that it might not be the amount of information given, that is important, but the exchange of information between patient and doctor in finding a treatment regimen suitable for the special needs of this patient. Targeted interventions might improve patient management. 40 To be able to give individualised advice, physicians need to be aware of each patient's view of his/her health problems and treatment options.
The literature suggests that NESW might influence patients' compliance. To our knowledge, no study so far has aimed at determining the contribution of all these factors on hypertensive patients' compliance within one study. Consequently, we developed a short survey instrument for primary care physicians, to aid physicians in determining which patients are less likely to comply with the therapy. Using this survey instrument, patients commencing treatment with ACE-inhibitor (Fosinopril) medication for hypertension were screened for their NESW characteristics.
Materials and methods

Survey instrument
The survey instrument for physicians was developed by the COMPASS study group and extensively pre-tested. The development of the survey instrument consisted of four phases. (i) Items were collected based on the literature on patients', compliance and adherence. (ii) Five experts in the treatment of patients with hypertension each rated the items for importance and clarity. Overlapping items were removed. Only items rated as important by all five experts were retained. (iii) The remaining items were presented to another independent group of health professionals, who each rated one of their current patients by means of the survey, and gave an estimate of the patients compliance in an interview. (iv) Consistency of the questionnaire rating with the interview rating was tested to establish the survey's validity.
The COMPASS survey consists of four subscales representing the NESW model. Each subscale includes three items (see the appendix), which doctors can rate on a 9-point Likert scale ranging from 'completely disagree' to 'completely agree'. Lower scores represent lower levels of compliance. A minimum overall score of 12 and a maximum overall score of 108 is possible. The minimum score within each subscale is 3 and the maximum subscale score is 27. Patients were collapsed on the basis of their overall compliance and subscale scores into groups with low, medium, and high compliance scores (Table 1) .
Patients
A total of 161 general practitioners and internal medicine physicians practising all over Austria participated in this study. The physicians received a detailed information package to explain the purpose of the study and how to use the COMPASS survey instrument. Participating doctors were advised to identify at least eight patients requiring treatment with Fosinopril. Of the 2389 recruited patients, 54.4% were women and the mean patient's age was 64.5 years. More than two-thirds (77.3%) of patients were treated for hypertension only and 17.3% had additional diagnoses of coronary heart Compliance in hypertensive patientsdisease. In 3.9% of patients, doctors gave the coronary heart disease as the main treatment reason. In 1.5%, the reason for the current treatment was missing from the forms. The treatment with Fosinopril was the first treatment for hypertension in 493 patients (20.6%), 1230 (51.5%) patients had received other treatment in the past, and no information about former treatment was given in 666 (27.9) of the patients. Patients were excluded from trial if they had been treated with Fosinopril before or if there were any contraindications to be treated with Fosinopril.
Study design
At baseline, physicians recorded patients' sociodemographic characteristics, patients' disease/illness features, and rated patients' compliance using the COMPASS survey instrument. A record was made of whether the patient had experienced a significant cardiovascular event in the past, and had previously undergone treatment for hypertension.
At the commencement of therapy with Fosinopril, physicians predicted if the patient would still be on treatment 6 months later. Treatment over the next 6-month period followed each physician's standard care. No special instructions were issued. After the 6-month period, patients' current treatment status was recorded.
Statistical analyses
A specialised data entry manager recorded the data. All data were descriptively analysed. The evaluation strategy was explorative. The statistical analysis was based on the 'intention to treat' principle employing the last-value technique. Data were analysed using student's t-test for independent samples and Wilcoxon-Mann-Whitney U-test. A special procedure was employed using configuration-frequency analysis to extract sensitivity and accuracy of the COMPASS survey instrument.
Results
Overall compliance
The mean patient overall compliance baseline score was 75.6. Almost all patients (97.3%) received a medium to high compliance score at baseline. Only a small percentage of patients had a low overall compliance score (2.7%). However, looking at the subscale results, about 10% of patients had low N and W subscale scores. Most patients compensated a low score in one subscale with a better performance in another subscale, which resulted in a high summary score. Highest compliance subscale scores (high score: 46.0%) were found in E (Table 2) .
Item analysis and subscale results
Comparatively low subscale scores at baseline in N were the result of doctors having the impression that patients might find it difficult to change their lifestyle (low score in 24.7% of patients) and to follow the doctors advice (low score in 21.5% of patients). A low score in the E subscale was mainly due to problems with the cooperation between treatment institutions (low score in 9.8% of patients) or problems with arranging follow-up visits (low score in 8.9% of patients). Reasons for a low W subscale score were patients' unawareness of secondary effects of hypertension on general health (low score in 13.9% of patients), difficulty in explaining the medication adequately to the patient (low score in 15.6% of patients), and the patients' perceived unwillingness to obtain additional information about their illness and treatment apart from their doctors' advice (low score in 31.0% of patients). Low scores in the S subscale in 22.3% of patients were mainly due to low levels of support by family and friends.
Patients' characteristics and compliance
Prior cardiovascular disease
Of all participating patients, 29.9% had a cardiovascular disease in the past. These were transitory ischaemic attacks (TIA) (13.9%), cardiac infarction (8.7%), stroke (6.0%), PTCA (3.5%), bypass (2.8%), and others (8.5%). No difference was found in the overall baseline compliance score between patients with or without a history of cardiovascular disease in the past. Patients who had a significant cardiovascular disease in the past received higher item scores in lifestyle changes, cooperation of treatment institutions, and support by family and friends ( Figure 1 ).
Prior medication
Prior medication was registered in 50.5% of all patients included in the COMPASS study. Physicians rated the baseline compliance summary score of these patients lower than those of patients who received their first treatment for cardiovascular Compliance in hypertensive patients R Schoberberger et al disease within this study (compliance summary score 74.9 vs 76.5; P ¼ 0.05) (Figure 2 ).
Prediction of 6-month compliance
Physicians predicted at baseline that 79.5%. of all patients would still take the prescribed medication 6 months later. This forecast correlated significantly with the overall compliance score. Patients expected to be still on treatment after 6 months had a mean compliance summary score of 77.7 compared to 67.7 in patients who were estimated to be non-compliant at 6-month follow-up (Po0.001). Patients predicted to be compliant at 6-month follow-up had significantly higher mean scores in all four subscales NESW ( Figure 3 ).
Noncompliance
Treatment was terminated in 107 (4.5%) patients by the treating physician. At 6-month follow-up, 167 (7.0%) patients had stopped the prescribed medication themselves (noncompliance). The treatment was terminated by the doctor because of side effects, reaching the treatment objective and change of treatment regimen. One reason for patients' noncompliance was low motivation to take the medication (13.2%). In most cases, however, no reason is known for the termination of the medication by the patient (Table 3) . No participating doctor had significantly more noncompliant patients than the other doctors.
Relationship between age, gender, prior coronary heart disease, and non-compliance Patients whose treatment was terminated by their doctors did not differ from all other patients.
However, noncompliant patients were found to differ significantly when compared to all other patients.
A significantly higher percentage of non-compliant patients were male compared to the overall sample (noncompliant patients: men ¼ 54.9%, women ¼ 45.1%, P ¼ 0.007). Noncompliant patients were found to be significantly younger (mean age ¼ 62.5 years) compared to the overall sample (mean age ¼ 64.5 years, P ¼ 0.03). Patients who had experienced a cardiovascular disease in the past were significantly less likely to belong to the 'noncompliant patients' group (4.3%) than those who had not (8.1%) (Po0.001).
Noncompliance and doctors' compliance estimate at baseline
Patients who were found to be noncompliant at 6-month follow-up had significantly lower baseline scores in all four compliance subscales NESW compared to patients whose treatment was ceased by the doctors and compared to the compliant patients, who still followed their treatment regimen (Table 4) .
While the mean scores of noncompliant patients were significantly lower than those of compliant patients, the confidence intervals for all patients were overlapping ( Table 4 ). The sensitivity of the survey instrument to truly detect noncompliant patients was estimated to be 82.6, with a specificity (true negative ratio) of 39.5.
Discussion
Adequate control of hypertension depends on a patient's motivation to follow the doctor's advice, to perform lifestyle changes, and to comply with the treatment. Doctors need to present the information Figure 1 Item scores for patients with or without a cardiovascular disease experience in the past (mean). Higher scores represent more favourable compliance scores.
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R Schoberberger et al and treatment advice in an understandable and motivating way. Both patients and doctors need to work together to increase patients' compliance. Early selection of patients with higher risk for noncompliance could be important to support these patients individually. The aim of the COMPASS study was to develop an easy-to-apply screening instrument, to help doctors estimate patient compliance at the commencement of treatment, to sensitise doctors for the importance of monitoring patients' compliance, and to allow planning of individualised interventions to enhance compliance. The results of this study show that the 12-item COMPASS survey instrument is useful to estimate patients' compliance. Patients who had stopped taking their medication at 6-month follow-up had significantly lower mean subscale and overall compliance scores at baseline compared to other patients. Noncompliant patients were significantly more likely to be male, to be of younger age, and to have no history of cardiovascular disease in the past.
The normative behaviour subscale (N) measures a patient's capacity to achieve lifestyle changes, to comply with recommendations, and to take the medication regularly. Patients within the COMPASS survey experienced the most difficulties in changing their lifestyle habits. Kravitz et al 15 examined patient recall of both medication-related and lifestyle-related physician recommendations. The recall of medication-related information was high (490%), whereas the recall of nonpharmacological advice (diet, exercise, self-care activities) was significantly lower (22-84%) . Simple advice by the doctor may not be enough to allow the change of habituated health-related behaviours like smoking, low level of exercise, or high fat intake. Achievement of lifestyle changes is, however, especially important for treatment success. For example, obesity was found to be the third most important factor to explain uncontrolled systolic blood pressure besides older age and left ventricular hypertrophy in patients treated for hypertension in the Figure 2 Differences in overall compliance, and item scores in patients with or without prior medication for hypertension (mean). Higher scores represent more favourable compliance scores. 41 Individualised training programmes by multidisciplinary teams including dietitians, health psychologists, and physical education experts might increase the percentage of patients who can successfully change their lifestyle. Based on the doctors' rating within the subscale N, more patients who had a cardiovascular event in the past achieved life-style changes compared to patients without a cardiovascular event in the past.
The Effective Structural Circumstances subscale E summarises organisational circumstances that could influence treatment success, such as effective doctor-patient communication under time constraints, patient monitoring, and level of cooperation between different treatment institutions. Arranging definite follow-up appointments was reported to be one of the most important physician-related factors to increase treatment compliance. 16 Furnham 17 suggested that patients need and want to be involved in planning and implementing the treatment regimen. Satisfaction with the consultation was found to be another important factor in predicting therapy adherence. 18 Satisfaction clearly is higher if there are no time constraints restricting open discussions of problems. 42 However, even if the physician's time is restricted, other medical personnel could fulfil the monitoring role. A small randomised trial tested the effectiveness of a pharmacist-initiated home blood pressure monitoring programme. In all, 16 patients in the intervention group received home blood pressure monitors to measure their blood pressure twice daily, a diary, and phone counselling. Unsatisfactory levels of blood pressure were reported to the general practitioner. The mean absolute reductions in blood pressure were significantly higher for patients in the intervention group. 19 The social support subscale S gives an estimate of the quality of the doctor-patient relationship and other favourable social resources available to the patient. Patients with little social support are less likely to be treated for hypertension and reach a controlled level of blood pressure less frequently Figure 3 Differences in overall compliance and the four subscale scores (NESW) in patients expected to be still adherent at 6 months compared to those who were expected to have stopped medication. Higher scores represent more favourable compliance scores. Compliance in hypertensive patients R Schoberberger et al than those with sufficient social support. 43 Professional support must step in the gap for these patients, while family or friends should be integrated to help stabilise the patients' treatment schedule. Fishman, 27 for example, conducted a short successful intervention, using a patient's family and friends to remind the patient to follow the treatment regimen. A recent review found partner-focused and structural strategies to be effective in increasing the adherence to nonpharmacological treatment for hypertension. 28 However, conflicting information and excess of information given to the patient by well-meaning friends and family may influence patient compliance negatively. 17 The fourth subscale of the COMPASS survey instrument investigates the knowledge level of the patient (W). Patient's knowledge about possible secondary effects of hypertension, openness towards discussions about medications, and additional advice by other health experts are assessed. Patients who received their first treatment for hypertension within the COMPASS study had higher scores in all three W items (Figure 2) . In semistructured interviews, Svensson et al 34 investigated reasons for adherence and nonadherence in hypertensive patients. interestingly, they found patients who adhered to be less involved in their treatment. They trusted their physicians, feared complications of hypertension, and had a desire to control their hypertension. Nonadherence was found to be an active decision, mostly because of drug-related side effects interfering with daily life. However, some nonadherent patients were found to have a misconception of their disease, and generally disliked taking any medication. [33] [34] [35] A further important result of the COMPASS study concerns patients' past cardiovascular experience.
Prior experience with a cardiovascular disease in the past increased the likelihood of treatment compliance. Patients with prior treatment failure and those with no former significant cardiovascular event could profit most from successful individualised support.
Overall, only a small percentage (7.0%) of all patients in this study were noncompliant. This is a very low percentage compared to results in the literature. A compliant person is usually defined as one who follows medical or health advice and/or shows behaviour that favours the intended health outcome. 43 To be compliant, a person must take at least 80% of the prescribed medication. 44, 45 It has been estimated that approximately 25-33% of all patients adhere to their prescribed medications, while 30-50% are completely noncompliant and the rest are partially compliant. 10 Estimates vary with the length of observation and depending on the definition of 'acceptable' compliance. 23, 40 However, some other more recent studies reported compliance rates close to 90%. 46, 47 Nuesch et al 47 discussed if higher compliance rates already reflected better acceptance of modern treatment with once daily regimes and comparatively mild side effects. The high compliance rate observed in our study could however be a result of increased awareness for compliance by completing the survey. Doctors may have also increased the level of support for the study participants compared to their usual care.
Doctors participating found the COMPASS survey instrument useful and took the opportunity to estimate patients' compliance and to differentiate between individual patients' needs. This is reflected in high overall compliance scores but low subscale scores given to about a quarter of all patients. The low noncompliance rate observed in this study is promising and warrants the use of the COMPASS Compliance in hypertensive patientsstudy survey instrument in further studies. However, as the results of this study are based on a selected and nonrandomised group of doctors (those who volunteered to participate), additional studies are necessary to replicate our findings. While the questionnaire sensitivity is good, its specificity needs to be improved. In the future, doctors can use this questionnaire to differentiate between patients, who might lack resources in any of the four areas, NESW, and can individually educate patients based on their needs. A treatment approach that observes all areas (NESW) could increase compliance in patients at risk and might reduce the likelihood of treatment failure.
